{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:37:03Z","timestamp":1787312223286,"version":"build-2736575974"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T00:00:00Z","timestamp":1724976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"The Scientific and Technological Program of Suzhou","award":["SKY2021064"],"award-info":[{"award-number":["SKY2021064"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-024-00782-2","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:04:05Z","timestamp":1724997845000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Drug-induced liver injury associated with atypical generation antipsychotics from the FDA Adverse Event Reporting System (FAERS)"],"prefix":"10.1186","volume":"25","author":[{"given":"Sidi","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanwei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,8,30]]},"reference":[{"issue":"Suppl 7","key":"782_CR1","first-page":"29","volume":"66","author":"RL Findling","year":"2005","unstructured":"Findling RL, Steiner H, Weller EB. Use of antipsychotics in children and adolescents. J Clin Psychiatry. 2005;66(Suppl 7):29\u201340.","journal-title":"J Clin Psychiatry"},{"issue":"12","key":"782_CR2","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","volume":"57","author":"MC Mauri","year":"2018","unstructured":"Mauri MC, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493\u2013528.","journal-title":"Clin Pharmacokinet"},{"key":"782_CR3","doi-asserted-by":"crossref","unstructured":"Orzelska-G\u00f3rka J, et al. New atypical antipsychotics in the treatment of Schizophrenia and depression. Int J Mol Sci, 2022. 23(18).","DOI":"10.3390\/ijms231810624"},{"issue":"2","key":"782_CR4","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/wps.20516","volume":"17","author":"CU Correll","year":"2018","unstructured":"Correll CU, Rubio JM, Kane JM. What is the risk-benefit ratio of long-term antipsychotic treatment in people with schizophrenia? World Psychiatry. 2018;17(2):149\u201360.","journal-title":"World Psychiatry"},{"issue":"10327","key":"782_CR5","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","volume":"399","author":"J Schneider-Thoma","year":"2022","unstructured":"Schneider-Thoma J, et al. Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis. Lancet. 2022;399(10327):824\u201336.","journal-title":"Lancet"},{"issue":"2","key":"782_CR6","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1055\/s-2008-1073117","volume":"28","author":"RJ Fontana","year":"2008","unstructured":"Fontana RJ. Acute liver failure due to drugs. Semin Liver Dis. 2008;28(2):175\u201387.","journal-title":"Semin Liver Dis"},{"issue":"13","key":"782_CR7","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.4254\/wjh.v7.i13.1761","volume":"7","author":"E Raschi","year":"2015","unstructured":"Raschi E, De Ponti F. Drug- and herb-induced liver injury: progress, current challenges and emerging signals of post-marketing risk. World J Hepatol. 2015;7(13):1761\u201371.","journal-title":"World J Hepatol"},{"key":"782_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s12916-016-0553-2","volume":"14","author":"IJ Onakpoya","year":"2016","unstructured":"Onakpoya IJ, Heneghan CJ, Aronson JK. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 2016;14:10.","journal-title":"BMC Med"},{"issue":"3","key":"782_CR9","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1007\/s00204-020-02963-4","volume":"95","author":"N Todorovi\u0107 Vukoti\u0107","year":"2021","unstructured":"Todorovi\u0107 Vukoti\u0107 N, et al. Antidepressants- and antipsychotics-induced hepatotoxicity. Arch Toxicol. 2021;95(3):767\u201389.","journal-title":"Arch Toxicol"},{"issue":"2","key":"782_CR10","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/00004714-200104000-00014","volume":"21","author":"I Gaertner","year":"2001","unstructured":"Gaertner I, et al. Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol. 2001;21(2):215\u201322.","journal-title":"J Clin Psychopharmacol"},{"issue":"7\u20138","key":"782_CR11","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1016\/S0278-5846(02)00263-4","volume":"26","author":"L Mouradian-Stamatiadis","year":"2002","unstructured":"Mouradian-Stamatiadis L, et al. Liver function tests during treatment with antipsychotic drugs: a case series of 23 patients. Prog Neuropsychopharmacol Biol Psychiatry. 2002;26(7\u20138):1409\u201311.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"6","key":"782_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1002\/jcla.10094","volume":"17","author":"MT Garcia-Unzueta","year":"2003","unstructured":"Garcia-Unzueta MT, et al. Alterations of liver function test in patients treated with antipsychotics. J Clin Lab Anal. 2003;17(6):216\u20138.","journal-title":"J Clin Lab Anal"},{"issue":"4","key":"782_CR13","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/00004714-199708000-00012","volume":"17","author":"M Hummer","year":"1997","unstructured":"Hummer M, et al. Hepatotoxicity of clozapine. J Clin Psychopharmacol. 1997;17(4):314\u20137.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"782_CR14","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.pnpbp.2006.03.014","volume":"30","author":"T Ozcanli","year":"2006","unstructured":"Ozcanli T, et al. Severe liver enzyme elevations after three years of olanzapine treatment: a case report and review of olanzapine associated hepatotoxicity. Prog Neuropsychopharmacol Biol Psychiatry. 2006;30(6):1163\u20136.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"5","key":"782_CR15","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1002\/hep.510290535","volume":"29","author":"K Selim","year":"1999","unstructured":"Selim K, Kaplowitz N. Hepatotoxicity of psychotropic drugs. Hepatology. 1999;29(5):1347\u201351.","journal-title":"Hepatology"},{"issue":"5","key":"782_CR16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1097\/WNF.0b013e31826818b6","volume":"35","author":"KF Marwick","year":"2012","unstructured":"Marwick KF, Taylor M, Walker SW. Antipsychotics and abnormal liver function tests: systematic review. Clin Neuropharmacol. 2012;35(5):244\u201353.","journal-title":"Clin Neuropharmacol"},{"issue":"10","key":"782_CR17","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s40264-016-0436-7","volume":"39","author":"M Slim","year":"2016","unstructured":"Slim M, et al. Hepatic safety of atypical antipsychotics: current evidence and future directions. Drug Saf. 2016;39(10):925\u201343.","journal-title":"Drug Saf"},{"key":"782_CR18","doi-asserted-by":"publisher","first-page":"160026","DOI":"10.1038\/sdata.2016.26","volume":"3","author":"JM Banda","year":"2016","unstructured":"Banda JM, et al. A curated and standardized adverse drug event resource to accelerate drug safety research. Sci Data. 2016;3:160026.","journal-title":"Sci Data"},{"issue":"1","key":"782_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","volume":"11","author":"EP van Puijenbroek","year":"2002","unstructured":"van Puijenbroek EP, et al. A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf. 2002;11(1):3\u201310.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"782_CR20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2190\/44WA-WXF7-3UHA-FDV1","volume":"34","author":"A Erdogan","year":"2004","unstructured":"Erdogan A, et al. Management of marked liver enzyme increase during clozapine treatment: a case report and review of the literature. Int J Psychiatry Med. 2004;34(1):83\u20139.","journal-title":"Int J Psychiatry Med"},{"issue":"6","key":"782_CR21","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/j.pnpbp.2007.05.005","volume":"31","author":"N Atasoy","year":"2007","unstructured":"Atasoy N, et al. A review of liver function tests during treatment with atypical antipsychotic drugs: a chart review study. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(6):1255\u201360.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"782_CR22","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/1471-244X-9-57","volume":"9","author":"KH Choi","year":"2009","unstructured":"Choi KH, et al. Effects of typical and atypical antipsychotic drugs on gene expression profiles in the liver of schizophrenia subjects. BMC Psychiatry. 2009;9:57.","journal-title":"BMC Psychiatry"},{"issue":"6 Pt 1","key":"782_CR23","first-page":"542","volume":"28","author":"G Dumortier","year":"2002","unstructured":"Dumortier G, et al. [Hepatic tolerance of atypical antipsychotic drugs]. Encephale. 2002;28(6 Pt 1):542\u201351.","journal-title":"Encephale"},{"key":"782_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1744-9081-2-37","volume":"2","author":"M Shimabukuro","year":"2006","unstructured":"Shimabukuro M, et al. Haloperidol treatment induces tissue- and sex-specific changes in DNA methylation: a control study using rats. Behav Brain Funct. 2006;2:37.","journal-title":"Behav Brain Funct"},{"issue":"10","key":"782_CR25","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s00702-005-0425-y","volume":"113","author":"C Mehler-Wex","year":"2006","unstructured":"Mehler-Wex C, et al. Microarray analysis reveals distinct gene expression patterns in the mouse cortex following chronic neuroleptic and stimulant treatment: implications for body weight changes. J Neural Transm (Vienna). 2006;113(10):1383\u201393.","journal-title":"J Neural Transm (Vienna)"},{"issue":"3","key":"782_CR26","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1097\/00004850-200505000-00009","volume":"20","author":"CU Pae","year":"2005","unstructured":"Pae CU, et al. Naturalistic observation on the hepatic enzyme changes in patients treated with either risperidone or olanzapine alone. Int Clin Psychopharmacol. 2005;20(3):173\u20136.","journal-title":"Int Clin Psychopharmacol"},{"issue":"5","key":"782_CR27","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1111\/j.1742-7843.2007.00198.x","volume":"102","author":"Z Halici","year":"2008","unstructured":"Halici Z, et al. Chronically administered risperidone did not change the number of hepatocytes in rats: a stereological and histopathological study. Basic Clin Pharmacol Toxicol. 2008;102(5):426\u201332.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"6","key":"782_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1097\/01.pra.0000422741.95118.9f","volume":"18","author":"SH Preskorn","year":"2012","unstructured":"Preskorn SH. Clinically important differences in the pharmacokinetics of the ten newer atypical antipsychotics: part 3. Effects of renal and hepatic impairment. J Psychiatr Pract. 2012;18(6):430\u20137.","journal-title":"J Psychiatr Pract"},{"issue":"1","key":"782_CR29","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1177\/070674370905400108","volume":"54","author":"DE Addington","year":"2009","unstructured":"Addington DE, et al. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study. Can J Psychiatry. 2009;54(1):46\u201354.","journal-title":"Can J Psychiatry"},{"issue":"2","key":"782_CR30","first-page":"5403","volume":"6","author":"JP Kane","year":"2014","unstructured":"Kane JP, O\u2019Neill FA. Clozapine-induced liver injury and pleural effusion. Ment Illn. 2014;6(2):5403.","journal-title":"Ment Illn"},{"issue":"1","key":"782_CR31","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1186\/s12911-019-0999-1","volume":"19","author":"R Liu","year":"2019","unstructured":"Liu R, Zhang P. Towards early detection of adverse drug reactions: combining pre-clinical drug structures and post-market safety reports. BMC Med Inf Decis Mak. 2019;19(1):279.","journal-title":"BMC Med Inf Decis Mak"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-024-00782-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-024-00782-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T06:07:20Z","timestamp":1724998040000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-024-00782-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,30]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["782"],"URL":"https:\/\/doi.org\/10.1186\/s40360-024-00782-2","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,30]]},"assertion":[{"value":"30 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This project was submitted for review through Advocate Health and was waived as this study was deemed non-human subject related research.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"59"}}